AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.08M
Average 0.32M
ACIU Interest Expense
Cost of servicing the company's debt during the period.
AC Immune S.A.NASDAQ: ACIU
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense growth accelerates
Q1 FY2026 interest expense of CHF 65K rose 20.4% year over year, ahead of the +3.8% change in trailing-twelve-month interest expense. Sequentially, it rose 56.0% from the prior quarter. Over 3 fiscal years it compounded at -18.7% a year.
Context
- Interest expense amounted to 5.3% of revenue in FY2025, up 4.9 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +20.4% holds above the trailing-twelve-month pace of +3.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
CHF · from the income statement
- Latest · FY2025
- 191K CHF
- Year-over-year change
- +43.6%
- 4-year CAGR
- -24.3%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 191K | +43.6% |
| FY2024 | 2024-12-31 | 133K | -24.4% |
| FY2023 | 2023-12-31 | 176K | -50.4% |
| FY2022 | 2022-12-31 | 355K | -38.9% |
| FY2021 | 2021-12-31 | 581K | — |
Interest Expense vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.8% is the 3rd highest of 6, against a peer median of -1.1%.
- Interest expense amounts to 4.2% of revenue for ACIU, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.64M USD | — | -38.1% | — | |
| LTM Mar 2026 | $8.49M USD | +11.7% | +28.9% | 12.5% | |
| LTM Mar 2026 | $2.42M USD | +48.5% | — | — | |
| LTM Mar 2026 | $1.89M USD | -1.1% | +4.0% | — | |
| LTM Mar 2026 | CHF 156.68K CHF | +3.8% | -18.7% | 4.2% | |
| LTM Mar 2026 | $94.83K USD | -92.3% | -57.7% | 19.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | $0 USD | -100.0% | -22.4% | 0.0% | |
| Peer median (excluding ACIU) | — | -1.1% | -22.4% | 0.0% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
| Cost of Revenue | 0 | 0 | 54.61M | 62.57M | 0 |
| Gross Profit | 0 | 3.94M | (39.81M) | (35.26M) | 3.57M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| Research & Development | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
| Selling, General & Admin | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
| Operating Expenses | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.5M |
| EBITDA | (70.01M) | (68.03M) | (51.83M) | (48.62M) | (67.75M) |
| EBITDA Margin | — | -1728.7% | -350.2% | -178.0% | -1896.2% |
| Operating Income | (79.01M) | (70.85M) | (53.62M) | (52.38M) | (68.86M) |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Income | 6.49M | 69K | 1.04M | 3.2M | 1.87M |
| Interest Expense | 581K | 355K | 176K | 133K | 191K |
| Other Income / Expenses | 6.02M | 107K | (599K) | 1.47M | (1.58M) |
| Income Before Tax | (72.99M) | (70.74M) | (54.22M) | (50.91M) | (70.45M) |
| Pre-Tax Margin | — | -1797.7% | -366.3% | -186.4% | -1971.6% |
| Income Tax Expense | 3K | 13K | 10K | 3K | 0 |
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (70.45M) |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1971.6% |
| EPS (Basic) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| EPS (Diluted) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| Weighted Avg Shares | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
| Weighted Avg Shares (Diluted) | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.